Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.41 |
| ▸ | SELE | P16581 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.41 |
| ▸ | FBP1 | P09467 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401241 | 0.77 | NR4A2 (0.50) | MAPK1PKMPAX8ATMNPSR1 | |
| SCHEMBL1821527 | 0.73 | NPSR1 (0.63) | MAPK1PKMPAX8ATMNPSR1 | |
| SCHEMBL8042105 | 0.68 | MAPK8 (0.56) | MAPK1PKMPAX8ATMNPSR1 | |
| SCHEMBL28449152 | 0.68 | PTPN11 (0.53) | MAPK1PKMPAX8ATMNPSR1 | |
| SCHEMBL28452078 | 0.67 | MAPK1 (0.56) | MAPK1PKMPAX8ATMNPSR1 | |
| SCHEMBL8048536 | 0.66 | FBP1 (0.47) | MAPK1PKMPAX8ATMNPSR1 | |
| SCHEMBL10535557 | 0.63 | FBP1 (0.72) | MAPK1NPSR1FBP1MAPTGAA | |
| SCHEMBL28461028 | 0.61 | ALDH1A1 (0.53) | MAPK1PKMPAX8ATMNPSR1 | |
| SCHEMBL8198195 | 0.61 | DOT1L (0.40) | — | |
| SCHEMBL28461401 | 0.61 | MAPK1 (0.51) | MAPK1PKMPAX8ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4681302-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| EP-2316834-A1 | Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-05-04 | — | — | EP | claimed |
| JP-2006513192-A | — | — | 2006-04-20 | — | — | JP | claimed |
| EP-1501829-A1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | Vertex Pharmaceuticals Incorporated (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2004058753-A1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040038992-A1 | Inhibitors of Jak protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | claimed |
| EP-2316834-A1 | Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7271179-B2 | Inhibitors of JAK protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1501829-A1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | Vertex Pharmaceuticals Incorporated (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004058753-A1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040038992-A1 | Inhibitors of Jak protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038992-A1 | Inhibitors of Jak protein kinase | JAK2, JAK1, JAK3 | MAPK1 221/4885PKM 744/4885PAX8 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.